VWWMG
PVLA

Vermillion & White Wealth Management Group’s Palvella Therapeutics PVLA Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-88
Closed -$9.21K – 568
2025
Q4 		$9.21K Hold
88
– – 0.01% 322
2025
Q3 		$5.52K Hold
88
– – ﹤0.01% 399
2025
Q2 		$1.98K Buy
+88
New +$2.07K ﹤0.01% 466

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vermillion & White Wealth Management Group's PVLA Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 88 shares — an estimated $9.21K sold.

Vermillion & White Wealth Management Group first reported a position in PVLA in Q2 2025 and held it in 3 quarters. The position peaked at $9.21K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Vermillion & White Wealth Management Group reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vermillion & White Wealth Management Group sold 88 Palvella Therapeutics shares in Q1 2026, an estimated $9.21K.
  • Vermillion & White Wealth Management Group first reported a position in Palvella Therapeutics in Q2 2025 and held it in 3 quarters.
  • Vermillion & White Wealth Management Group's Palvella Therapeutics position peaked at $9.21K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.